

Rothesay House
134 Douglas Street
Glasgow G2 4HF
Tel: 0871 220 5434
Fax: 0871 220 5435
E-mail: patientsupport@roycastle.org
Web: www.roycastle.org

Dr Carole Longson
Centre for Health Technology Evaluation
National Institute for Health and Clinical Excellence
Level 1A City Tower
Piccadilly Plaza
Manchester
M1 4BD

22nd June 2010

Dear Dr Longson,

Response to the Appraisal Committee Document – Erlotinib for the maintenance treatment of non-small-cell lung cancer

This letter is a response, on behalf of the Roy Castle Lung Cancer Foundation.

We are disappointed that the recently issued ACD on the use of Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer, reveals that the Committee is minded not to recommend this therapy.

We understand that the manufacturer is in the process of submitting further data, reflecting the stable disease licence indication in maintenance treatment. We would wish to remind the Committee of the overall poor prognosis and low survival rates for this patient group. Even relatively small improvements in survival and quality of life, as compared with the current established therapy, are of real importance to patients. We hope, that during its deliberations with this additional data, the Appraisal Committee will be mindful of this and take it in to account.

If you require further information please contact us at the address above.

Yours sincerely,

